Roberta Assaloni, Italy

AAS2 Bassa Friulana-Isontina SSD di Diabetologia

Presenter Of 1 Presentation

HYBRID CLOSED-LOOP SYSTEM IMPROVES GLUCOSE CONTROL IN PATIENTS TREATED WITH MULTIPLE DAILY INJECTION AND CGM OR INTEGRATED INSULIN PUMP AND CGM OR SENSOR-AUGMENTED PUMP

Session Name
CLOSED-LOOP SYSTEM AND ALGORITHM
Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Date
20.02.2020, Thursday
Session Time
09:30 - 15:30
Channel
E-Poster Area
Lecture Time
09:30 - 09:31

Abstract

Background and Aims

The MiniMed 670G Hybrid Closed-Loop (HCL) System improves glucose control and reduces glucose variability. There are no data whether HCL Systems achieve different results in T1DM patients treated with multiple daily injection and continuous glucose monitoring (MDI+CGM) or integrated insulin pump and CGM (CSII+CGM) or sensor-augmented pump therapy with predictive low glucose suspend (PLSG) feature. Aim of our study was to evaluate the effect on metabolic control of the switch from MDI+CGM, CSII+CGM or SAP with PLGS in type 1 diabetic patients.

Methods

Baseline clinical characteristics were presented as means and SD. One-way repeated measures ANOVA test was used to verify changes at 12 weeks from baseline in mean blood glucose, SD, TIR, TAR, TBR, Total Insulin dose and % of Basal Insulin.

Results

32 adults with type 1 diabetes (mean age 41,9 + 9,7; duration of diabetes 22 + 12,5; BMI 24,7 + 4,1), who had been using MDI + CGM (n=12) or CSII + CGM (n=11) or SAP therapy (n=9) were evaluated after switching to the 670G System. After 12 weeks a reduction of HbA1c (-0,39% p <0.001), mean glucose and SD (-9,7 mg/dl and 5,8 mg/dl p 0,003 and < 0,001) were observed. TIR increased significantly (+9,7% p < 0,001), in parallel with a reduction in TAR (-8,6% p 0,003) and TBR (-0,87% p 0,044).

Conclusions

Switching to the 670G System significantly improved glucose control in patients previously treated with MDI+CGM and CSII+CGM. Furthermore, similar results were obtained in patients treated with SAP with PLGS feature.

Hide